PDGFRA and gastrointestinal stromal tumor: Investigational agents—including bezuclastinib, crenolanib, IDRX-42, and olverembatinib—are being developed to overcome complex resistance mechanisms and to expand options for rare GIST subtypes such as SDH-deficient and KIT/PDGFRA wild-type tumors.